| Day 30 CD3+CD8+ T cells | |||||
|---|---|---|---|---|---|
| Predictor | Beta (Unstd.) | SE | Beta (Std.) | 95% CI (lower, upper) | p-value |
| Intercept | 1,434.38 | 721.98 | – | −421.52, 3,290.28 | 0.104 |
| Sexa | 182.05 | 152.43 | 0.464 | −209.79, 573.89 | 0.286 |
| Age at ublituximab start, years | −13.22 | 7.12 | −0.789 | −31.51, 5.07 | 0.122 |
| BMI (kg/m2) | −15.17 | 24.90 | −0.241 | −79.17, 48.82 | 0.569 |
| No. of previous DMTs | −34.85 | 56.35 | −0.220 | −179.71, 110.01 | 0.563 |
| Gadolinium-enhancing lesions at baseline MRI | −98.88 | 205.60 | −0.202 | −627.40, 429.65 | 0.651 |
Model statistics: R² = 0.481; adjusted R² = −0.037; F(5, 5) = 0.93; p = 0.532.